Drug Name:
PARAGARD T380A Rx

Generic Name and Formulations:
Copper-bearing intrauterine contraceptive device.
Company:
The Cooper Companies
Therapeutic Use:
Indications for PARAGARD T380A:
Intrauterine contraception.
Adult:
See literature. ≥16yrs: Insert into uterine cavity. Check placement shortly after first menses. Replace at least every 10 years.
Children:
<16yrs: not recommended.
Contraindications:
Uterine abnormality. Uterine or cervical malignancy. Pelvic inflammatory disease or risk thereof. Postpartum or postabortal endometritis in the past 3 months. Genital actinomycosis. Abnormal genital bleeding. Cervicitis. Wilson's disease. Retained IUD. Pregnancy or suspicion of pregnancy.
Warnings/Precautions:
Vaginal bleeding. Ectopic pregnancy. Immunocompromised. Immunosuppressive therapy. Avoid medical diathermy. Assure suitable uterine anatomy before insertion. Remove the device if evidence of partial expulsion, perforation, or breakage.
Pharmacological Class:
IUD.
Adverse Reactions:
Bleeding, cramps, anemia, dyspareunia, pelvic infection, infertility, ectopic pregnancy, uterine or cervical perforation, embedment or fragmentation of device, septicemia (during pregnancy), spontaneous abortion, vasovagal reactions (during insertion or removal).
How Supplied:
Device—1, 5
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer